Bayer Aktiengesellschaft (BAYRY)

OTCMKTS · Delayed Price · Currency is USD
7.06
+0.07 (1.00%)
May 29, 2025, 3:58 PM EDT
-6.74%
Market Cap 27.60B
Revenue (ttm) 50.34B
Net Income (ttm) -3.52B
Shares Out n/a
EPS (ttm) -3.59
PE Ratio n/a
Forward PE 5.37
Dividend 0.02 (0.32%)
Ex-Dividend Date Apr 29, 2025
Volume 74,872
Average Volume 810,077
Open 7.04
Previous Close 6.99
Day's Range 7.00 - 7.06
52-Week Range 4.79 - 8.58
Beta 0.98
RSI 62.21
Earnings Date May 13, 2025

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]

Sector Healthcare
Founded 1863
Employees 90,587
Stock Exchange OTCMKTS
Ticker Symbol BAYRY
Full Company Profile

Financial Performance

In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.

Financial numbers in EUR Financial Statements

News

Bayer wins EU watchdog's endorsement for longer Eylea treatment intervals

German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment Eylea, giving it a potential edge over Roche'...

7 days ago - Reuters

Bayer Launches Centafore Imaging Core Lab to Support Imaging for Clinical Trials and Software as a Medical Device Development

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the launch of its Imaging Core Lab Services under the brand name Centafore. With over 25 years of experience supporting more than 200 clinical tr...

7 days ago - Business Wire

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

TEL AVIV, Israel , May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI ...

8 days ago - Benzinga

Bayer Highlights New Data from Oncology and Women's Health Portfolios at 2025 ASCO Annual Meeting

WHIPPANY, N.J.--(BUSINESS WIRE)--The latest data from studies across Bayer's oncology and women's health portfolios will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) ...

9 days ago - Business Wire

Bayer CEO on managing through the good and bad: Call out the problems

Bayer CEO Bill Anderson takes the stage at the 2025 CNBC CEO Council Summit to talk to leaders about managing through uncertainty and tackling problems head-on.

9 days ago - CNBC

Dr. Yesmean Wahdan from Bayer Discusses Women's Health Month with YourUpdateTV

May is Women's Health Month – Dr. Yesmean Wahdan Shares Important and Timely Tips to Help Women Prioritize Their Health at Every Life Stage May is Women's Health Month – Dr. Yesmean Wahdan Shares Impo...

10 days ago - GlobeNewsWire

Bayer seeks Roundup settlement, explores Monsanto bankruptcy, WSJ reports

Bayer is seeking to resolve lawsuits related to its Roundup weedkiller, while exploring a bankruptcy for its Monsanto unit if the settlement plan fails, the Wall Street Journal reported on Thursday, c...

14 days ago - Reuters

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy

The agricultural giant is preparing to place its U.S. subsidiary Monsanto in bankruptcy if a settlement with tort plaintiffs fails

14 days ago - WSJ

Bayer US head says FDA chief reassured pharma executives of timely reviews

Bayer Pharmaceuticals' chief operating officer said the head of the top U.S. drug regulator recently reassured industry executives that the Food and Drug Administration would meet its targets for revi...

14 days ago - Reuters

Bayer exec: Trump pharma tariffs would negatively impact R&D

Tariffs on pharma products could hinder R&D efforts, says Bayer exec. Read more here

14 days ago - Seeking Alpha

Bayer Profit Drops 35%, Launches Overhaul To Counter Generic Pressure

Bayer AG (OTC: BAYRY) reported on Tuesday that the first quarter of 2025 net profit was 1.3 billion euros (around $1.45 billion), down from 2 billion euros a year ago. The company reported: Adjusted ...

16 days ago - Benzinga

Bayer Profit Drops 35%, Launches Overhaul To Counter Generic Pressure

Bayer AG BAYRY reported on Tuesday that the first quarter of 2025 net profit was 1.3 billion euros (around $1.45 billion), down from 2 billion euros a year ago.

16 days ago - Benzinga

Bayer A.G. (BAYZF) Q1 2025 Earnings Call Transcript

Bayer A.G. (OTCPK:BAYZF) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ETCompany ParticipantsBill Anderson - Chairman & CEOWolfgang Nickl -...

16 days ago - Seeking Alpha

Bayer: U.S. Supreme Court could decide in June whether it will hear glyphosate case

Bayer said on Tuesday that the U.S. Supreme Court could decide as early as next month whether it will hear the German company's request to sharply limit litigation that could run into the billions of ...

16 days ago - Reuters

Bayer earnings drop by a third as woes force first German factory closure in 161 years

Net profit falls to €1.3bn as litigation costs and slowing sales weigh on conglomerate

17 days ago - Financial Times

Bayer shares soar as company records strong cancer drug demand

Bayer’s strong first quarter performance was mainly driven by its pharmaceuticals division, even as its crop-science branch lagged.

17 days ago - Euronews

Bayer posts smaller than expected 7.4% drop in quarterly adjusted profit

Bayer on Tuesday posted a slower decline in first-quarter adjusted earnings than the market had feared as strong prescription numbers for new drugs offset a drop in its soy and cotton seed business.

17 days ago - Reuters